2,3-dinor, 6-keto-PGF1alpha

2,3-dinor, 6-keto-pgf1alpha is a lipid of Fatty Acyls (FA) class.

Cross Reference

There are no associated biomedical information in the current reference collection.

Current reference collection contains 782 references associated with 2,3-dinor, 6-keto-PGF1alpha in LipidPedia. Due to lack of full text of references or no associated biomedical terms are recognized in our current text-mining method, we cannot extract any biomedical terms related to diseases, pathways, locations, functions, genes, lipids, and animal models from the associated reference collection.

Users can download the reference list at the bottom of this page and read the reference manually to find out biomedical information.


Here are additional resources we collected from PubChem and MeSH for 2,3-dinor, 6-keto-PGF1alpha

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with 2,3-dinor, 6-keto-PGF1alpha

MeSH term MeSH ID Detail
Body Weight D001835 333 associated lipids
Inflammation D007249 119 associated lipids
Hypertension D006973 115 associated lipids
Diabetes Mellitus, Type 2 D003924 87 associated lipids
Atherosclerosis D050197 85 associated lipids
Liver Cirrhosis D008103 67 associated lipids
Diabetes Mellitus, Type 1 D003922 56 associated lipids
Thrombosis D013927 49 associated lipids
Coronary Artery Disease D003324 47 associated lipids
Endometriosis D004715 29 associated lipids
Ascites D001201 25 associated lipids
Cerebrovascular Disorders D002561 25 associated lipids
Cardiovascular Diseases D002318 24 associated lipids
Pregnancy Complications D011248 19 associated lipids
Down Syndrome D004314 18 associated lipids
Alcoholic Intoxication D000435 15 associated lipids
Angina, Unstable D000789 14 associated lipids
Cerebral Hemorrhage D002543 13 associated lipids
Respiratory Syncytial Virus Infections D018357 10 associated lipids
Aortic Aneurysm D001014 8 associated lipids
Per page 10 20 50 | Total 25

NCBI Entrez Crosslinks

All references with 2,3-dinor, 6-keto-PGF1alpha

Download all related citations
Per page 10 20 50 100 | Total 191
Authors Title Published Journal PubMed Link
Fischer C and Meese CO Simultaneous determination of 6-oxo-prostaglandin F1 alpha and 2,3-dinor-6-oxo-prostaglandin F1 alpha in biological fluids by stable isotope dilution and negative ion chemical ionization mass spectrometry. 1985 Biomed. Mass Spectrom. pmid:2931130
Edlund A et al. Myocardial ischaemia triggers formation of thromboxane. 1987 Lancet pmid:2887865
Gréen K et al. Deficient prostacyclin formation after acute myocardial infarction. 1987 Lancet pmid:2883378
Aitokallio-Tallberg A et al. Urinary excretion of prostacyclin and thromboxane degradation products in patients with ovarian malignancy: effect of cytostatic treatment. 1989 Br. J. Cancer pmid:2803956
pmid:27137142
Barrow SE et al. Cigarette smoking: profiles of thromboxane- and prostacyclin-derived products in human urine. 1989 Biochim. Biophys. Acta pmid:2679889
Kühl PG et al. Endogenous formation of prostanoids in neonates with persistent pulmonary hypertension. 1989 Arch. Dis. Child. pmid:2673060
Rousson D et al. Increased in vivo biosynthesis of prostacyclin and thromboxane A2 in chronic idiopathic thrombocytopenic purpura. 1989 Br. J. Haematol. pmid:2669929
Grèen K et al. Pronounced reduction of in vivo prostacyclin synthesis in humans by acetaminophen (paracetamol). 1989 Prostaglandins pmid:2664901
Förstermann U et al. An increase in the ratio of thromboxane A2 to prostacyclin in association with increased blood pressure in patients on cyclosporine A. 1989 Prostaglandins pmid:2662262
Chiabrando C et al. Quantitative profiling of 6-ketoprostaglandin F1 alpha, 2,3-dinor-6-ketoprostaglandin F1 alpha, thromboxane B2 and 2,3-dinor-thromboxane B2 in human and rat urine by immunoaffinity extraction with gas chromatography-mass spectrometry. 1989 J. Chromatogr. pmid:2613794
Ritter JM et al. Differential effect of aspirin on thromboxane and prostaglandin biosynthesis in man. 1989 Br J Clin Pharmacol pmid:2590611
pmid:25669623
Knapp HR and Salem N Formation of PGI3 in the rat during dietary fish oil supplementation. 1989 Prostaglandins pmid:2557651
Beckmann ML et al. Prostacyclin synthesis is increased during propranolol therapy for essential hypertension. 1989 Adv. Prostaglandin Thromboxane Leukot. Res. pmid:2526468
Vesterqvist O and Gréen K Effects of naproxen on the in vivo synthesis of thromboxane and prostacyclin in man. 1989 Eur. J. Clin. Pharmacol. pmid:2515064
Lupinetti MD et al. Thromboxane biosynthesis in allergen-induced bronchospasm. Evidence for platelet activation. 1989 Am. Rev. Respir. Dis. pmid:2508524
Koivisto VA et al. Stimulation of prostacyclin synthesis by physical exercise in type I diabetes. 1989 Diabetes Care pmid:2507264
Ruth V et al. Urinary excretion of prostacyclin metabolites in infants born after maternal preeclampsia or with birth asphyxia. 1989 Biol. Neonate pmid:2506939
Hamazaki T et al. Urinary excretion of PGI2/3-M and recent N-6/3 fatty acid intake. 1989 Prostaglandins pmid:2503856
Ross S et al. Association of cyclooxygenase-2 genetic variant with cardiovascular disease. 2014 Eur. Heart J. pmid:24796340
pmid:24671522
Song WL et al. Niacin and biosynthesis of PGDâ‚‚by platelet COX-1 in mice and humans. 2012 J. Clin. Invest. pmid:22406532
Skarke C et al. Comparative impact on prostanoid biosynthesis of celecoxib and the novel nonsteroidal anti-inflammatory drug CG100649. 2012 Clin. Pharmacol. Ther. pmid:22278334
Wennmalm A et al. Non-invasive assessment of the cardiovascular eicosanoids, thromboxane A2 and prostacyclin, in randomly sampled males, with special reference to the influence of inheritance and environmental factors. 1990 Clin. Sci. pmid:2176952
Lynch CM et al. The role of thromboxane A(2) in the pathogenesis of intrauterine growth restriction associated with maternal smoking in pregnancy. 2011 Prostaglandins Other Lipid Mediat. pmid:21723954
Piret A et al. Increased platelet aggregability and prostacyclin biosynthesis induced by intense physical exercise. 1990 Thromb. Res. pmid:2140206
Edlund A et al. Acipimox stimulates skin blood flow by a cyclo-oxygenase-dependent mechanism. 1990 Eur. J. Clin. Pharmacol. pmid:2125938
Henriksson P et al. Thromboxane synthase inhibition: "endoperoxide shunt phenomenon" does not occur in healthy humans in vivo. 1990 Prostaglandins pmid:2106716
Ylikorkala O et al. Urinary excretion of prostacyclin and thromboxane metabolites in climacteric women: effect of estrogen-progestin replacement therapy. 1990 Prostaglandins pmid:2106714
Yuhki K et al. [Prostaglandin I2 and its metabolites]. 2010 Nippon Rinsho pmid:20960743
Fukushima H et al. Mechanisms underlying early development of pulmonary vascular obstructive disease in Down syndrome: An imbalance in biosynthesis of thromboxane A2 and prostacyclin. 2010 Am. J. Med. Genet. A pmid:20583254
Hotter G et al. Altered levels of tissue and urinary prostacyclin in rats subjected to pancreas transplantation. 1991 Prostaglandins pmid:2052738
Vernon WB Prostaglandins and pancreas transplantation. 1991 Prostaglandins pmid:2052737
Blatnik M and Steenwyk RC Quantification of urinary PGEm, 6-keto PGF(1alpha) and 2,3-dinor-6-keto PGF(1alpha) by UFLC-MS/MS before and after exercise. 2010 Prostaglandins Other Lipid Mediat. pmid:20416393
Wennmalm A et al. Relation between tobacco use and urinary excretion of thromboxane A2 and prostacyclin metabolites in young men. 1991 Circulation pmid:2022025
Rasmanis G et al. Prostacyclin production in myocardial infarction in the acute phase and during follow-up. 1991 J. Intern. Med. pmid:1997639
Foudi N et al. Altered reactivity to norepinephrine through COX-2 induction by vascular injury in hypercholesterolemic rabbits. 2009 Am. J. Physiol. Heart Circ. Physiol. pmid:19783781
Greer IA et al. Synergistic inhibitory effects of adrenoceptor antagonists and prostacyclin, and umbilical artery-derived prostacyclin-like activity on platelet aggregation. 1990 May-Jun Eur. J. Obstet. Gynecol. Reprod. Biol. pmid:1970789
Ward PS et al. Excretion of metabolites of prostacyclin and thromboxane by rats with nephrotoxic nephritis: effects of interleukin-1. 1991 Br. J. Pharmacol. pmid:1933130
Zhao L et al. Low-dose oral sirolimus reduces atherogenesis, vascular inflammation and modulates plaque composition in mice lacking the LDL receptor. 2009 Br. J. Pharmacol. pmid:19220291
Foudi N et al. Selective cyclooxygenase-2 inhibition directly increases human vascular reactivity to norepinephrine during acute inflammation. 2009 Cardiovasc. Res. pmid:18952694
Presser SC et al. Simultaneous measurements of prostacyclin and thromboxane metabolites during the menstrual cycle. 1991 Am. J. Obstet. Gynecol. pmid:1892191
Signore C et al. Markers of oxidative stress and systemic vasoconstriction in pregnant women drinking > or =48 g of alcohol per day. 2008 Alcohol. Clin. Exp. Res. pmid:18715278
Aitokallio-Tallberg AM et al. Urinary excretion of degradation products of prostacyclin and thromboxane is increased in patients with gestational choriocarcinoma. 1991 Cancer Res. pmid:1868436
Schwartz JI et al. Effects of etoricoxib and comparator nonsteroidal anti-inflammatory drugs on urinary sodium excretion, blood pressure, and other renal function indicators in elderly subjects consuming a controlled sodium diet. 2007 J Clin Pharmacol pmid:17925592
Arnaud J et al. Effect of low dose antioxidant vitamin and trace element supplementation on the urinary concentrations of thromboxane and prostacyclin metabolites. 2007 J Am Coll Nutr pmid:17914127
Neulen J et al. Arachidonic acid metabolism and prostaglandin production by primate preimplantation blastocysts. 1991 Prostaglandins pmid:1775634
Capone ML et al. Human pharmacology of naproxen sodium. 2007 J. Pharmacol. Exp. Ther. pmid:17473175
Kurki T et al. Urinary excretion of prostacyclin and thromboxane metabolites in threatened preterm labor: effect of indomethacin and nylidrin. 1992 Am. J. Obstet. Gynecol. pmid:1733190